tirzepatide surpass-4 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial SURPASS-4 trial: Tirzepatide slows rate

Microdosing may help sustain behavioral and physiological changes that support long-term weight maintenance

Glucagon-like peptide 21

However, there are certain challenges

The dosing schedule of Wegovy is as follows: Starting dose: 0.25 mg once weekly for the first 4 weeks Titration phase: The titration schedule of Wegovy is as follows: Weeks 1-4: 0.25 mg once weekly Weeks 5-8: 0.5 mg once weekly Weeks 9-12: 1 mg once weekly, if you tolerate the previous dosage

Jacc Basic Transl

The objective of this review is to examine the effects of non-insulin glucose-lowering drugs on weight loss in patients with type 2 diabetes